Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Income towards Parent Company: 2013-2024

Historic Income towards Parent Company for CytomX Therapeutics (CTMX) over the last 12 years, with Dec 2024 value amounting to $31.9 million.

  • CytomX Therapeutics' Income towards Parent Company fell 348.06% to -$14.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.0 million, marking a year-over-year increase of 102.59%. This contributed to the annual value of $31.9 million for FY2024, which is 5700.88% up from last year.
  • As of FY2024, CytomX Therapeutics' Income towards Parent Company stood at $31.9 million, which was up 5,700.88% from -$569,000 recorded in FY2023.
  • In the past 5 years, CytomX Therapeutics' Income towards Parent Company registered a high of $31.9 million during FY2024, and its lowest value of -$115.9 million during FY2021.
  • Its 3-year average for Income towards Parent Company is -$22.7 million, with a median of -$569,000 in 2023.
  • As far as peak fluctuations go, CytomX Therapeutics' Income towards Parent Company plummeted by 78.76% in 2021, and later spiked by 5,700.88% in 2024.
  • Yearly analysis of 5 years shows CytomX Therapeutics' Income towards Parent Company stood at -$64.8 million in 2020, then tumbled by 78.76% to -$115.9 million in 2021, then climbed by 14.29% to -$99.3 million in 2022, then soared by 99.43% to -$569,000 in 2023, then surged by 5,700.88% to $31.9 million in 2024.